B Cell News and Research

RSS

Type 2 diabetes more prevalent in women with large abdominal fat cells

Middle-aged women with large abdominal fat cells have a higher risk of developing type 2 diabetes later in life compared to women with smaller fat cells. Waist circumference divided by body height can also be used to determine which women are at risk. This is shown in a new study from the Sahlgrenska Academy at the University of Gothenburg, Sweden.

21 Sep 2009

H1N1 infected people continue to shed live virus days after the symptoms

ABC News and other outlets are reporting that two studies released on Tuesday suggest that people infected with the H1N1 virus continue to shed virus after the point where current recommendations say they can resume their normal activities.

19 Sep 2009

KCI to conduct discussion on limb surgeries and amputations

Kinetic Concepts, Inc. (KCI) will sponsor a CME-accredited panel discussion, “The Role of NPWT in the Team Approach to Limb Salvage: Case Studies,” at the 3rd Annual Georgetown Diabetic Limb Salvage conference September 24-26.

19 Sep 2009

NovoStent completes enrollment for its SAMBA Stent and Delivery System trial

NovoStent Corporation, a privately held medical device company, today announced the completion of enrollment earlier this summer in the company’s European clinical trial evaluating the use of its SAMBATM Stent and Delivery System in the treatment of superficial femoral and popliteal artery disease.

19 Sep 2009

Pfizer Oncology to present early-stage research of investigational agents for cancer treatment

Pfizer Oncology will present data from across its portfolio, including results from long-term follow-up of Aromasin® (exemestane tablets) in a study of early breast cancer, updated study results from a Phase 3 study of Sutent® (sunitinib malate) in pancreatic neuroendocrine tumors (NET), and early-stage research of investigational agents PF-02341066 and figitumumab (CP-751,871) in patients with non-small cell lung cancer (NSCLC).

19 Sep 2009

Millennium's sNDA for VELCADE granted priority review by the FDA

Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has granted priority review to the Company’s supplemental new drug application (sNDA) for VELCADE. The sNDA contains long-term overall survival (OS) data from the landmark VISTA trial examining the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).

19 Sep 2009

Bioniche announces fiscal 2009 year-end results

Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its 2009 fiscal year ended June 30, 2009.

19 Sep 2009

EPO and growth factor therapy safe for anemic MDS patients

Myelodysplastic syndromes (MDS), a group of blood disorders that can lead to acute myeloid leukemia (AML) in some patients, often cause severe anemia (when the body lacks a sufficient number of functional red blood cells).

18 Sep 2009

National Medal of Science awarded to J. Craig Venter

J. Craig Venter, Ph.D., founder, president and chairman of the J. Craig Venter Institute (JCVI), has been named a recipient of this year's National Medal of Science. Dr. Venter will be awarded the Medal from President Obama on October 7 at a White House ceremony.

18 Sep 2009

BioSante and Cell Genesys encourage stockholders to vote shares

BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) and Cell Genesys, Inc. (NASDAQ:CEGE), today jointly announced that RiskMetrics Group – ISS Governance Services, a leading proxy advisory firm, has recommended that BioSante and Cell Genesys stockholders vote “FOR” the adoption of the merger agreement between BioSante and Cell Genesys at their upcoming respective special meeting of stockholders scheduled to be held on September 30, 2009.

18 Sep 2009

'Pathway to a Cure' walk event in California

Satellite Healthcare, one of the nation's first and leading providers of kidney dialysis services and a major sponsor of nephrology research, today announced their sponsorship of The Polycystic Kidney Disease Foundation's "Pathway to a Cure" walk event in California's capital of Sacramento.

18 Sep 2009

Metabolic Research to participate in the Olympia Expo

Metabolic Research, Inc., makers of Stemulite, will have a booth in the Olympia Expo at the Las Vegas Convention Center South Hall, September 25th and 26th. The Stemulite booth will feature Corey and Paul Simpson, well-known super athlete trainers joined by Cristi Cuellar, Miss Bikini Mexico International Elite Champion.

18 Sep 2009

Study to determine the expression of S100A2 and p63 genes

As a member of the S100 family, S100A2 is considered a candidate tumor-suppressor gene. Recently, p63 gene, a new member of the p53 gene family, has been studied in the fields of tumorigenesis, cell apoptosis and tissue growth. At present, few studies have been carried out on the expression and relationship of S100A2 and p63 in EC.

18 Sep 2009

Pharmacyclics announces financial results for fourth quarter and FY 2009

Pharmacyclics, Inc. today reported financial results for its fourth quarter and fiscal year ended June 30, 2009. During the fourth quarter of fiscal 2009 Pharmacyclics incurred a GAAP net loss of $5.4 million, or $0.20 per share, compared to a net loss of $4.6 million, or $0.18 per share for the fourth quarter of fiscal 2008.

18 Sep 2009

Researchers study the role of stem cells in development of liver cancer

Penn State College of Medicine researchers, in collaboration with colleagues at the University of Southern California, have taken an important step in understanding the role of stem cells in development of liver cancer.

18 Sep 2009

Study reveals microRNAs affect tumor progression

UCSF researchers have identified collections of tiny molecules known as microRNAs that affect distinct processes critical for the progression of cancer. The findings, they say, expand researchers' understanding of the important regulatory function of microRNAs in tumor biology and point to new directions for future study and potential treatments.

18 Sep 2009

National Institutes of Health funds for thymus research

The National Institutes of Health have awarded, as part of the American Reinvestment and Recovery Act, a two-year, $2 million grant to a University of Georgia genetics researcher and her colleagues for studies on the thymus, the organ in humans that produces disease-fighting T-cells.

18 Sep 2009

SEQUENOM's first laboratory developed cystic fibrosis test launched

SEQUENOM, Inc. today announced that the company's first laboratory developed test, the SensiGene(TM) Cystic Fibrosis (CF) Carrier Screening test, has been launched.

18 Sep 2009

Notice of Allowance issued by PTO for OSI's EGFR drug

OSI Pharmaceuticals, Inc. announced today that the U.S. Patent & Trademark Office has issued a “Notice of Allowance” in OSI’s reissue application for U.S. Patent No.5,747,498 (the ‘498) composition of matter patent for Tarceva® (erlotinib). The reissued patent will replace the original ‘498 patent and have the same November 2018 expiration date.

18 Sep 2009

Juvaris BioTherapeutics completes first close on Series B equity financing

Juvaris BioTherapeutics, Inc., a biotechnology company developing adjuvanted vaccines for infectious diseases, announced that it has completed the first close on its Series B equity financing of up to $25 million led by SV Life Sciences (SVLS) along with existing investor, Kleiner Perkins Caufield & Byers (KPCB).

18 Sep 2009